View source for Document:EU CHMP Guidelines -

<noinclude>{{#set:
|DocReference=EU  CHMP Guidelines  -
|DocValidityArea=EU
|DocScopes=HM
|DocName=CHMP Guidelines
|DocVersion=-
|DocStatus=N.A.
|DocType=Corpus of texts
|DocLanguage=EN
|DocDescription=The Committee for Medicinal Products for Human Use (CHMP) is the European Medicines Agency's (EMA) committee responsible for human medicines.

Clinical efficacy and safety guideline categories :
- Alimentary tract and metabolism
- Blood and blood forming organs
- Blood products (including biotechnological alternatives)
- Cardiovascular system
- Dermatologicals
- Genito-urinary system and sex hormones
- Anti-infectives for systemic use
- Antineoplastic and immunomodulating agents
- Rheumatology/musculoskeletal system
- Nervous system
- Respiratory system
- Orally inhaled products
- Radiopharmaceuticals and diagnostic agents
- Allergy/Immunology
- Biostatistics
- General (Including ICH guidelines E1 

To be noted:
- INS/GCP/46309/2012 – Classification and analysis of the GCP inspection findings of GCP inspections conducted at the request of the CHMP
|DocRestricted=No
|DocSubmittedBy=Florian Adragna
|DocContributors=
}}</noinclude>

{{DocumentBox
|reference=EU  CHMP Guidelines  -
|validity_area=EU
|scopes=HM
|doc_name=CHMP Guidelines
|version=-
|status=N.A.
|doc_type=Corpus of texts
|language=EN
|description=The Committee for Medicinal Products for Human Use (CHMP) is the European Medicines Agency's (EMA) committee responsible for human medicines.

Clinical efficacy and safety guideline categories :
- Alimentary tract and metabolism
- Blood and blood forming organs
- Blood products (including biotechnological alternatives)
- Cardiovascular system
- Dermatologicals
- Genito-urinary system and sex hormones
- Anti-infectives for systemic use
- Antineoplastic and immunomodulating agents
- Rheumatology/musculoskeletal system
- Nervous system
- Respiratory system
- Orally inhaled products
- Radiopharmaceuticals and diagnostic agents
- Allergy/Immunology
- Biostatistics
- General (Including ICH guidelines E1 

To be noted:
- INS/GCP/46309/2012 – Classification and analysis of the GCP inspection findings of GCP inspections conducted at the request of the CHMP
|official_link=https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp
|restricted=No
|submitted_by=Florian Adragna
|contributors=
}}